CGenetix a pioneering biotechnology company focused on precision diagnostics in transplantation medicine, today announces the acquisition of two exclusive patent licenses that significantly strengthen its position in the field of epigenetic biomarker discovery for kidney transplantation.
CGenetix develops the new generation of liquid biopsy biomarkers to evaluate organs damages during a pathological process.